Mostrar el registro sencillo del ítem
Caracterización de los aspectos clínicos, métodos diagnósticos, manejo y evolución de la enfermedad trofoblástica gestacional en una institución de tercer nivel de Risaralda, 2015-2021
| dc.contributor.advisor | Marín Giraldo, María del Pilar | |
| dc.contributor.author | Narvaez Maldonado, Carlos Fernando | |
| dc.contributor.author | Sanchez Sierra, Astrid Carolina | |
| dc.contributor.author | Hernández Gómez, Jairo Alonso | |
| dc.date.accessioned | 2023-01-24T21:22:17Z | |
| dc.date.available | 2023-01-24T21:22:17Z | |
| dc.date.issued | 2022 | |
| dc.identifier.uri | https://digitk.areandina.edu.co/handle/areandina/4676 | |
| dc.description | 78 páginas : tablas, ilustraciones ; 58 cm. | spa |
| dc.description.abstract | La enfermedad trofoblástica gestacional constituye un conjunto de trastornos del tejido trofoblástico placentario que se derivan de anormalidades en el proceso de fertilización, su incidencia varía ampliamente según la región estudiada y se pueden presentar la mayoría de casos en extremos de edades. Dado la poca frecuencia de la misma no se tiene una gran cantidad de literatura reportada o de estudios prospectivos o ensayos clínicos por lo que se requieren estudios que ayuden a fomentar el desarrollo de nuevas investigaciones que permitan ampliar los conocimientos sobre la enfermedad. | spa |
| dc.description.tableofcontents | Consideraciones generales.-- Pregunta de investigación.-- Objetivo de investigación.-- Justificación.-- Marco referencial.-- Metodología.-- Resultados.-- Conclusiones.-- Recomendaciones.-- Bibliografía. | spa |
| dc.format.extent | 78 páginas | spa |
| dc.format.mimetype | application/pdf | spa |
| dc.language.iso | spa | spa |
| dc.publisher | Bogotá : Fundación Universitaria del Área Andina , 2022 | spa |
| dc.rights | EL AUTOR-ESTUDIANTE, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto, la obra es de su exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: en caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL ESTUDIANTE-AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la Fundación Universitaria del Área Andina actúa como un tercero de buena fe. | spa |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | spa |
| dc.title | Caracterización de los aspectos clínicos, métodos diagnósticos, manejo y evolución de la enfermedad trofoblástica gestacional en una institución de tercer nivel de Risaralda, 2015-2021 | spa |
| dc.type | Trabajo de grado - Especialización | spa |
| dc.rights.license | Atribución-NoComercial-SinDerivadas 4.0 Internacional (CC BY-NC-ND 4.0) | spa |
| dc.subject.armarc | Medicina clínica | |
| dc.subject.armarc | Diagnóstico | |
| dc.subject.armarc | Tumores trofoblásticos | |
| dc.contributor.educationalvalidator | Marín Giraldo, María del Pilar | |
| dc.publisher.place | Pereira | spa |
| dc.relation.references | Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic Neoplasia. Vol. 17, JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press; 2019. p. 1396–401. | spa |
| dc.relation.references | Eiriksson L, Dean E, Sebastianelli A, Salvador S, Comeau R, Jang JH, et al. Guideline No. 408: Management of Gestational Trophoblastic Diseases. Journal of Obstetrics and Gynaecology Canada. 2021 Jan 1;43(1):91-105.e1. | spa |
| dc.relation.references | Parker VL, Tidy JA. Current management of gestational trophoblastic disease | spa |
| dc.relation.references | Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. International Journal of Gynecology and Obstetrics. 2021 Oct 1;155(S1):86–93. | spa |
| dc.relation.references | Santaballa A, García Y, Herrero A, Laínez N, Fuentes J, de Juan A, et al. SEOM clinical guidelines in gestational trophoblastic disease (2017). Clinical and Translational Oncology. 2018 Jan 1;20(1):38–46. | spa |
| dc.relation.references | Horowitz NS, Eskander RN, Adelman MR, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol [Internet]. 2021;163(3):605–13. Available from: https://www.sciencedirect.com/science/article/pii/S0090825821014219 | spa |
| dc.relation.references | Villegas-Mejía CR, Chacón-Cardona JA, Villegas-Jaramillo M. Enfermedad trofoblástica gestacional en un centro oncológico de Caldas – Colombia durante el periodo 2001 – 2014. Revista Médicas UIS [Internet]. 2017 Dec 1;30(3):39–49. Available from: http://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/7294/7552 | spa |
| dc.relation.references | Joneborg U, Folkvaljon Y, Papadogiannakis N, Lambe M, Marions L. Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. Acta Oncol (Madr). 2018 Aug 3;57(8):1094–9 | spa |
| dc.relation.references | Aurore F, Khadidja B, Ginette R, Ulrike MH, Jean-Christophe T, Frédérique SB, et al. Gestational trophoblastic disease in Switzerland: Retrospective study of the impact of a regional reference centre. Swiss Med Wkly. 2021;151(5–6). | spa |
| dc.relation.references | Descargues P, Hajri T, Massardier J, Lotz JP, Devouassoux-Shisheboran M, Allias Montmayeur F, et al. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. Am J Obstet Gynecol. 2021;225(4):401.e1-401.e9. | spa |
| dc.relation.references | Jauniaux E, Memtsa M, Johns J, Ross JA, Jurkovic D. New insights in the pathophysiology of complete hydatidiform mole. Placenta. 2018;62:28–33. | spa |
| dc.relation.references | al Wahaibi F, al Ghaithi H, AlShamsi R, Gowri V, al Rawahi T. Gestational Trophoblastic Disease: Prevalence, Management and Follow-Up at a Tertiary Center in Oman—An 11-Year Study. Indian J Gynecol Oncol [Internet]. 2019;17(4):88. Available from: https://doi.org/10.1007/s40944-019-0332-z | spa |
| dc.relation.references | Coyle C, Short D, Jackson L, Sebire NJ, Kaur B, Harvey R, et al. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. Gynecol Oncol. 2018;148(2):254–7. | spa |
| dc.relation.references | Albright BB, Myers ER, Moss HA, Ko EM, Sonalkar S, Havrilesky LJ. Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2021;225(5):513.e1-513.e19 | spa |
| dc.relation.references | Hoeijmakers YM, Eysbouts YK, Massuger LFAG, Dandis R, Inthout J, van Trommel NE, et al. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement. Gynecol Oncol [Internet]. 2021;163(3):531–7. Available from: https://www.sciencedirect.com/science/article/pii/S0090825821013858 | spa |
| dc.relation.references | Lin LH, Maestá I, Braga A, Sun SY, Fushida K, Francisco RPV, et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017;145(1):88–95. | spa |
| dc.relation.references | Usui H, Qu J, Sato A, Pan Z, Mitsuhashi A, Matsui H, et al. Gestational Trophoblastic Neoplasia From Genetically Confirmed Hydatidiform Moles: Prospective Observational Cohort Study. International Journal of Gynecologic Cancer [Internet]. 2018 Nov 1;28(9):1772. Available from: http://ijgc.bmj.com/content/28/9/1772.abstract | spa |
| dc.relation.references | Zheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, et al. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology. 2020;33(10):1979–88. | spa |
| dc.relation.references | Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, et al. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2018;223:50–5. Available from: https://www.sciencedirect.com/science/article/pii/S0301211518300496 | spa |
| dc.relation.references | Mylvaganam G, Allanson E, Allanson B, Philp S, Pather S, Farrell R, et al. Assessment of current follow-up for complete molar pregnancies: A single centre review. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2021 Apr 1;61(2):213–6. | spa |
| dc.relation.references | Khosravirad A, Zayeri F, Baghestani AR, Yoosefi M, Bakhtiyari M. Predictive power of human chorionic gonadotropin in post-molar gestational trophoblastic neoplasia: A longitudinal roc analysis. Int J Cancer Manag. 2017;10(9) | spa |
| dc.relation.references | Subbaiah M, Raj A, Durairaj J, Keepanasseril A. Role of hysteroscopy and ultrasound in early identification of post-molar gestational trophoblastic neoplasia. European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2020;254:33–7. Available from: https://www.sciencedirect.com/science/article/pii/S0301211520305704 | spa |
| dc.relation.references | Alifrangis C, Seckl MJ. Genetics of gestational trophoblastic neoplasia: An update for the clinician. Vol. 6, Future Oncology. 2010. p. 1915–23. | spa |
| dc.relation.references | Nica A, Bouchard-Fortier G, Covens A. 34 Gestational Trophoblastic Disease Hydatidiform Mole, Nonmetastatic and Metastatic Gestational Trophoblastic Tumor: Diagnosis and Management. | spa |
| dc.relation.references | Lurain JR. Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Vol. 203, American Journal of Obstetrics and Gynecology. Mosby Inc.; 2010. p. 531–9. | spa |
| dc.relation.references | Lin LH, Polizio R, Fushida K, Francisco RPV. Imaging in Gestational Trophoblastic Disease. Vol. 40, Seminars in Ultrasound, CT and MRI. W.B. Saunders; 2019. p. 332–49. | spa |
| dc.relation.references | Lok C, van Trommel N, Massuger L, Golfier F, Seckl M, Abreu MH, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May 1;130:228–40. | spa |
| dc.relation.references | Al Wahaibi F, al Ghaithi H, AlShamsi R, Gowri V, al Rawahi T. Gestational Trophoblastic Disease: Prevalence, Management and Follow-Up at a Tertiary Center in Oman—An 11-Year Study. Indian J Gynecol Oncol [Internet]. 2019;17(4):88. Available from: https://doi.org/10.1007/s40944-019-0332-z | spa |
| dc.relation.references | Albright BB, Myers ER, Moss HA, Ko EM, Sonalkar S, Havrilesky LJ. Surveillance for gestational trophoblastic neoplasia following molar pregnancy: a cost-effectiveness analysis. Am J Obstet Gynecol. 2021;225(5):513.e1-513.e19. | spa |
| dc.relation.references | Alifrangis C, Seckl MJ. Genetics of gestational trophoblastic neoplasia: An update for the clinician. Vol. 6, Future Oncology. 2010. p. 1915–23. | spa |
| dc.relation.references | Aurore F, Khadidja B, Ginette R, Ulrike MH, Jean-Christophe T, Frédérique SB, et al. Gestational trophoblastic disease in Switzerland: Retrospective study of the impact of a regional reference centre. Swiss Med Wkly. 2021;151(5–6) | spa |
| dc.relation.references | ● Braga A, Biscaro A, do Amaral Giordani JM, Viggiano M, Elias KM, Berkowitz RS, et al. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia? European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2018;223:50–5. Available from: https://www.sciencedirect.com/science/article/pii/S0301211518300496 | spa |
| dc.relation.references | Coyle C, Short D, Jackson L, Sebire NJ, Kaur B, Harvey R, et al. What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients. Gynecol Oncol. 2018;148(2):254–7. | spa |
| dc.relation.references | Descargues P, Hajri T, Massardier J, Lotz JP, Devouassoux-Shisheboran M, Allias Montmayeur F, et al. Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization in a retrospective cohort of 7761 patients in France. Am J Obstet Gynecol. 2021;225(4):401.e1-401.e9. | spa |
| dc.relation.references | Eiriksson L, Dean E, Sebastianelli A, Salvador S, Comeau R, Jang JH, et al. Guideline No. 408: Management of Gestational Trophoblastic Diseases. Journal of Obstetrics and Gynaecology Canada. 2021 Jan 1;43(1):91-105.e1. | spa |
| dc.relation.references | Elias KM, Berkowitz RS, Horowitz NS. State-of-the-art workup and initial management of newly diagnosed molar pregnancy and postmolar gestational trophoblastic Neoplasia. Vol. 17, JNCCN Journal of the National Comprehensive Cancer Network. Harborside Press; 2019. p. 1396–401. | spa |
| dc.relation.references | Hoeijmakers YM, Eysbouts YK, Massuger LFAG, Dandis R, Inthout J, van Trommel NE, et al. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement. Gynecol Oncol [Internet]. 2021;163(3):531–7. Available from: https://www.sciencedirect.com/science/article/pii/S0090825821013858 | spa |
| dc.relation.references | Horowitz NS, Eskander RN, Adelman MR, Burke W. Epidemiology, diagnosis, and treatment of gestational trophoblastic disease: A Society of Gynecologic Oncology evidenced-based review and recommendation. Gynecol Oncol [Internet]. 2021;163(3):605–13. Available from: https://www.sciencedirect.com/science/article/pii/S0090825821014219 | spa |
| dc.relation.references | Jauniaux E, Memtsa M, Johns J, Ross JA, Jurkovic D. New insights in the pathophysiology of complete hydatidiform mole. Placenta. 2018;62:28–33. | spa |
| dc.relation.references | Joneborg U, Folkvaljon Y, Papadogiannakis N, Lambe M, Marions L. Temporal trends in incidence and outcome of hydatidiform mole: a retrospective cohort study. Acta Oncol (Madr). 2018 Aug 3;57(8):1094–9. | spa |
| dc.relation.references | Khosravirad A, Zayeri F, Baghestani AR, Yoosefi M, Bakhtiyari M. Predictive power of human chorionic gonadotropin in post-molar gestational trophoblastic neoplasia: A longitudinal roc analysis. Int J Cancer Manag. 2017;10(9). | spa |
| dc.relation.references | Lin LH, Maestá I, Braga A, Sun SY, Fushida K, Francisco RPV, et al. Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: A retrospective multicenter cohort and literature review. Gynecol Oncol. 2017;145(1):88–95. | spa |
| dc.relation.references | Lin LH, Polizio R, Fushida K, Francisco RPV. Imaging in Gestational Trophoblastic Disease. Vol. 40, Seminars in Ultrasound, CT and MRI. W.B. Saunders; 2019. p. 332–49. | spa |
| dc.relation.references | Lok C, van Trommel N, Massuger L, Golfier F, Seckl M, Abreu MH, et al. Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease. Eur J Cancer. 2020 May 1;130:228–40. | spa |
| dc.relation.references | Lurain JR. Gestational trophoblastic disease I: Epidemiology, pathology, clinical presentation and diagnosis of gestational trophoblastic disease, and management of hydatidiform mole. Vol. 203, American Journal of Obstetrics and Gynecology. Mosby Inc.; 2010. p. 531–9. | spa |
| dc.relation.references | Mylvaganam G, Allanson E, Allanson B, Philp S, Pather S, Farrell R, et al. Assessment of current follow-up for complete molar pregnancies: A single centre review. Australian and New Zealand Journal of Obstetrics and Gynaecology. 2021 Apr 1;61(2):213–6. | spa |
| dc.relation.references | Ngan HYS, Seckl MJ, Berkowitz RS, Xiang Y, Golfier F, Sekharan PK, et al. Diagnosis and management of gestational trophoblastic disease: 2021 update. International Journal of Gynecology and Obstetrics. 2021 Oct 1;155(S1):86–93 Nica A, Bouchard-Fortier G, Covens A. 34 Gestational Trophoblastic Disease Hydatidiform Mole, Nonmetastatic and Metastatic Gestational Trophoblastic Tumor: Diagnosis and Management | spa |
| dc.relation.references | Parker VL, Tidy JA. Current management of gestational trophoblastic disease. | spa |
| dc.relation.references | Santaballa A, García Y, Herrero A, Laínez N, Fuentes J, de Juan A, et al. SEOM clinical guidelines in gestational trophoblastic disease (2017). Clinical and Translational Oncology. 2018 Jan 1;20(1):38–46. | spa |
| dc.relation.references | Subbaiah M, Raj A, Durairaj J, Keepanasseril A. Role of hysteroscopy and ultrasound in early identification of post-molar gestational trophoblastic neoplasia. European Journal of Obstetrics & Gynecology and Reproductive Biology [Internet]. 2020;254:33–7. Available from: https://www.sciencedirect.com/science/article/pii/S0301211520305704 | spa |
| dc.relation.references | Usui H, Qu J, Sato A, Pan Z, Mitsuhashi A, Matsui H, et al. Gestational Trophoblastic Neoplasia From Genetically Confirmed Hydatidiform Moles: Prospective Observational Cohort Study. International Journal of Gynecologic Cancer [Internet]. 2018 Nov 1;28(9):1772. Available from: http://ijgc.bmj.com/content/28/9/1772.abstract | spa |
| dc.relation.references | Villegas-Mejía CR, Chacón-Cardona JA, Villegas-Jaramillo M. Enfermedad trofoblástica gestacional en un centro oncológico de Caldas – Colombia durante el periodo 2001 – 2014. Revista Médicas UIS [Internet]. 2017 Dec 1;30(3):39–49. Available from: http://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/7294/755 2 | spa |
| dc.relation.references | Zheng XZ, Qin XY, Chen SW, Wang P, Zhan Y, Zhong PP, et al. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease. Modern Pathology. 2020;33(10):1979–88. | spa |
| dc.rights.accessrights | info:eu-repo/semantics/closedAccess | spa |
| dc.type.content | Text | spa |
| dc.type.version | info:eu-repo/semantics/publishedVersion | spa |
| dc.type.coarversion | http://purl.org/coar/version/c_970fb48d4fbd8a85 | spa |
| dc.rights.coar | http://purl.org/coar/access_right/c_abf2 | spa |
| dc.description.degreelevel | Especialización | spa |
| dc.description.degreename | Especialista en Epidemiología | spa |
| dc.description.program | Especialización en Epidemiología | spa |
| dc.publisher.faculty | Facultad de Ciencias de la Salud y del Deporte | spa |
| dc.relation.indexed | LaReferencia | spa |
Ficheros en el ítem
Este ítem aparece en la(s) siguiente(s) colección(ones)
Excepto si se señala otra cosa, la licencia del ítem se describe como EL AUTOR-ESTUDIANTE, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto, la obra es de su exclusiva autoría y tiene la titularidad sobre la misma. PARÁGRAFO: en caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL ESTUDIANTE-AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la Fundación Universitaria del Área Andina actúa como un tercero de buena fe.
